OncoDiag logo — Innovative Solutions for Cancer Diagnostics

OncoDiag

Innovative Solutions for Cancer Diagnostics

Founded 2013 6 employees Series A Total: $4.10M Biotechnology, Health Care

General Information

Company Name OncoDiag
Founded Year 2013
Employees 6
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with OncoDiag. To contact OncoDiag, visit oncodiag.fr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About OncoDiag

OncoDiag is a biotech startup founded in 2012, offering innovative solutions for cancer diagnostics. The company focuses on the development and commercialization of solutions for the detection, diagnosis, and monitoring of cancers, with a priority on bladder, colorectal, and prostate cancer. With its recent €2.50M Series A investment at 15 March 2021, OncoDiag has secured funding from a consortium of investors including Angels Santé, Normandie Participations, Normandie Business Angels, Les Business Angels des Grandes Écoles, SFINE, Paris Business Angels. The startup's flagship product, Urodiag®, is a molecular tool known for its high performance in terms of sensitivity and specificity, addressing a critical medical need in the surveillance of bladder cancers. With its focus on public health challenges and the strong financial backing from reputable investors, OncoDiag exhibits the potential for significant growth and impact in the biotechnology and healthcare sectors.

Taxonomy: cancer diagnostics, medical innovation, oncology, bladder cancer, colorectal cancer, prostate cancer, molecular tools, public health, biotech startup, clinical research, medical monitoring, sensitivity and specificity

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €1.00M 1
Bpifrance
15 Mar 2021
Series A €2.50M 6
Angels Santé, Normandie Participations +4
15 Mar 2021
Angel Round €600.00K 2
Angels Santé, Normandie Business Angels
20 Dec 2018
Venture Round Undisclosed 1
AGORANOV
01 Apr 2014

OncoDiag Alternatives & Competitors

View All Alternatives
OncoDiag vs

Developing innovative vaccines for prostate cancer patients and a test to determine their effectiven...

Venture round
Biotechnology, Health Care
OncoDiag vs
Capio Biosciences
Capio Biosciences United States

Our Vision: To be the world’s leading liquid biopsy company providing valuable clinical information...

Series A
4 employees
Biotechnology, Health Care
OncoDiag vs

Eliminating cancer misdiagnosis by launching a new diagnostic test in 2023 and operating a boutique...

Grant
37 employees
Biotechnology, Health Care

FAQ About OncoDiag

Innovative Solutions for Cancer Diagnostics
OncoDiag was founded in 2013.
OncoDiag operates in Biotechnology and Health Care. Its work centres on cancer diagnostics, medical innovation, oncology and bladder cancer.
OncoDiag has approximately 6 employees.
OncoDiag has completed 4 funding rounds, raising a total of $4.10M. The latest funding stage is Series A.
Top alternatives and competitors to OncoDiag include Madison Vaccines, Capio Biosciences, MultiplexDX International, Agensys, Elphogene, s.r.o.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OncoDiag and Madison Vaccines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OncoDiag, https://bouncewatch.com/company/oncodiag, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes